SCHEMBL7255805

SCHEMBL7255805

c1ccc2c(c1)CCc1cccnc1C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.45
DRD2 P14416 3/20 0.39
DRD3 P35462 2/20 0.39
DRD1 P21728 1/20 0.39
DRD4 P21917 1/20 0.39
DRD5 P21918 1/20 0.39
TSHR P16473 1/20 0.39
GRIN1 Q05586 6/20 0.38
GRIN2B Q13224 6/20 0.38
GRIN2D O15399 2/20 0.38
GRIN3B O60391 2/20 0.38
GRIN2A Q12879 2/20 0.38
GRIN2C Q14957 2/20 0.38
GRIN3A Q8TCU5 2/20 0.38
METAP2 P50579 1/20 0.37
HTR2C P28335 2/20 0.36
CYP1A2 P05177 1/20 0.36
CHRM2 P08172 1/20 0.36
HTR1A P08908 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21479447 0.86 ALOX15 (0.40) DRD2DRD3DRD1DRD4DRD5
SCHEMBL4228551 0.85 CYP2A6 (0.43) CYP2A6DRD2DRD3DRD1DRD4
Fumaric Acid SCHEMBL29403191 0.85 HRH1 (0.42) CYP2A6TSHRCYP1A2HRH1KDM4E
SCHEMBL7424121 0.84
SCHEMBL17413659 0.81 DRD2 (0.42) DRD2DRD3TSHRGRIN1GRIN2B
SCHEMBL8348677 0.81
SCHEMBL29538838 0.81 HRH1 (0.45) DRD2DRD3DRD1DRD4HTR2C
SCHEMBL7255918 0.81 HRH1 (0.45) DRD2DRD3DRD1DRD4HTR2C
SCHEMBL9948370 0.81 ALOX15 (0.36) DRD2DRD3DRD1DRD4DRD5
SCHEMBL21691013 0.80 CYP2D6 (0.47) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595234-B2 Bioactive benzocycloheptene analogues from himachalenes and its applications COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-04-07 US disclosed
CN-114616229-B Tricyclic compounds and pharmaceutical uses thereof 镇斗生物科技股份公司 2024-09-03 CN disclosed
CN-116898799-B Desloratadine oral preparation and preparation method thereof 哈尔滨圣泰生物制药有限公司 2024-04-30 CN disclosed
CN-117447468-A Bazedoxifene derivative and preparation method and application thereof 中国药科大学 2024-01-26 CN disclosed
US-20230382860-A1 Bioactive Benzocycloheptene Analogues From Himachalenes and its Applications COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-30 US disclosed
CN-116898799-A Desloratadine oral preparation and preparation method thereof 哈尔滨圣泰生物制药有限公司 2023-10-20 CN disclosed
CN-112220748-B Desloratadine oral liquid preparation and preparation method thereof 江苏阿尔法药业股份有限公司 2023-07-07 CN disclosed
CN-115616122-A Method for separating and measuring related substances of loratadine starting material by liquid chromatography 北京万全德众医药生物技术有限公司 2023-01-17 CN disclosed
US-20230002349-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF JD BIOSCIENCE INC. (KR) 2023-01-05 US disclosed
EP-4053116-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF JD Bioscience Inc. (KR) 2022-09-07 EP disclosed
US-6127366-A ANTICARCINOGENIC OR ANTITUMOR AGENTS MERCK & CO., INC. (US) 2000-10-03 US disclosed
EP-1035852-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2000-09-20 EP disclosed
US-6054466-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 2000-04-25 US disclosed
US-6015817-A IMIDAZOLE-SUBSTITUTED THIENO(3,2-C)PYRIDINE DERIVATIVES; ANTICARCINOGENIC AGENTS, VIRICIDES; NERVOUS SYSTEM DISORDERS, VISION DEFECTS, KIDNEY DISEASES MERCK & CO., INC. (US) 2000-01-18 US disclosed
US-5977134-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1999-11-02 US disclosed
US-5972966-A AND THE FARNESYLATION OF THE ONCOGENE PROTEIN RAS MERCK & CO., INC. (US) 1999-10-26 US disclosed
WO-1999027933-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1999-06-10 WO disclosed
WO-1999028314-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1999-06-10 WO disclosed
WO-1999028313-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1999-06-10 WO disclosed
EP-0042544-B1 NOVEL ANTIHISTAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1984-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595234-B2 Bioactive benzocycloheptene analogues from himachalenes and its applications CNR2, HK2, PIK3C2A CYP2A6 154/4885DRD2 657/4885DRD3 1179/4885
US-20230002349-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TPH1, SLC6A4, TPH2 CYP2A6 225/4885DRD2 148/4885DRD3 220/4885
US-20230382860-A1 Bioactive Benzocycloheptene Analogues From Himachalenes and its Applications HK2, GPR119, PIK3CD CYP2A6 255/4885DRD2 684/4885DRD3 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.